AMG 623, which has completed Phase Ib studies in systemic lupus erythematosus patients, is a peptide fusion protein that binds to B-cell activating factor (BAFF). Anthera anticipates initiating Phase II studies in 2008.
Paul Truex, president and CEO of Anthera Pharmaceuticals, said: “AMG 623 has the potential to be an important treatment for a variety of immunological diseases, such as lupus, where there is a need for therapies with improved safety and efficacy.”